Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 2;15(4):733-747.
doi: 10.1158/2159-8290.CD-24-1071.

Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL

Yi-Jiun Su  1   2 , Anne Marijn Kramer  1 , Mark P Hamilton  1   3 , Neha Agarwal  1   3 , Hrishikesh K Srinagesh  1 , John H Baird  4 , Bita Sahaf  3   5 , Adam Kuo  3   5 , Zachary J Ehlinger  3   5 , Moksha H Desai  3   5 , Skyler P Rietberg  3   5 , Ramya Tunuguntla  3 , Shabnum Patel  3 , Harshini Chinnasamy  3 , Nikolaos Gkitsas-Long  3 , Dorota D Klysz  3 , Annie Kathleen Brown  3 , Sushma Bharadwaj  1   3 , Saurabh Dahiya  1   3 , Melody Smith  1   3 , Lori Muffly  1   3 , Crystal L Mackall  1   3   6   7 , Zinaida Good  3   7   8 , Steven A Feldman  3 , David B Miklos  1   3 , Matthew J Frank  1   3
Affiliations

Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL

Yi-Jiun Su et al. Cancer Discov. .

Abstract

Late leukapheresis (>6 months after CAR19) resulted in less residual CAR19, higher CAR22 CD4+ naïve T and TCM cells, less TEM cells, and higher CD8+ TCM cells, but similar clinical outcomes to those with early leukapheresis. CAR22 responses were associated with higher transduction efficiency and CD8+ TCM and less CD8+ TEM cells.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Conflicts of Interest

A.M.K.: Patent rights for CAT CAR in targeting CD19 and receive royalties from Autolus Therapeutics PLC.

M.P.H.: Consulting or Advisory Role: Kite Pharmaceuticals.

J.H.B.: Consulting for Kite Pharma-Gilead. Research support from Kite Pharma-Gilead, Cargo Therapeutics, Genentech-Roche, Regeneron Pharmaceuticals, and Janssen.

L.M.: Research support from Adaptive Biotechnologies and Servier Laboratories; consulting for Amgen, Pfizer.

C.L.M.: Founder, equity, consulting for Cargo Therapeutics. Founder, equity, consulting and Director of Link Cell Therapies. Royalties from NIH, for CAR22. Consulting for Immatics, Ensoma. Research funding from Lyell Immunopharma and Tune Therapeutics.

Z.G.: Consulting for Mubadala Ventures and Boom Capital Ventures. Research support from Kite Pharma-Gilead and 10x Genomics. Honoraria from Standard Biotools and Sangamo Therapeutics.

S.A.F.: Consulting or Advisory Role: Autolomous, FreshWind Bio, MicroFluidX (MFX), Achieve Clinics, University of Oslo (Center for Advanced Cell Therapy), Genentech and Lyell.

D.B.M.: Consulting for Kite Pharma-Gilead, Juno Therapeutics-Celgene, Novartis, Janssen, and Pharmacyclics. Research support from Kite Pharma-Gilead, Allogene, Cargo therapeutics, Pharmacyclics, Miltenyi Biotec, and Adaptive Biotechnologies.

M.J.F.: Consulting for Kite Pharma-Gilead, Adaptative Biotechnologies, ADC Therapeutics and Cargo Therapeutics. Research support from Kite-Pharma-Gilead, Allogene Therapeutics, CARGO Therapeutics and Adaptative Biotechnologies.

Y.J.S, N.A., H.K.S., B.S., A.K., Z.J.E., M.H.D., S.P.R., R.T., S.P., H.C., H.G.L., D.D.K., A.K.B., S.B., S.D., and M.S. have no competing financial interests to declare.

References

    1. Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 2023;141(19):2307–15 - PMC - PubMed
    1. Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales M-A, Ghobadi A, et al. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med 2023;389(2):148–57 - PubMed
    1. Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2021;22(10):1403–15 - PubMed
    1. Abramson JS, Palomba ML, Gordon LI, Lunning M, Wang M, Arnason J, et al. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood 2024;143(5):404–16 - PubMed
    1. Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood 2023;141(14):1675–84 - PMC - PubMed

MeSH terms

LinkOut - more resources